查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571666

子宮頸癌治療市場規模、佔有率、趨勢分析報告：按類型、治療方法、最終用途、地區和細分市場預測，2024-2030 年

Cervical Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment, By End-use (Hospital & Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

子宮頸癌治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球子宮頸癌治療市場規模將達117.4億美元，2024年至2030年複合年成長率為5.4%。

治療滲透率的提高和疾病盛行率的上升預計將推動未來幾年的市場成長。 HPV 主要透過性行為傳播，但也可能由其他因素引起，例如口服避孕藥、多重性伴侶、吸菸和 HIV 感染。 HPV有100多種株，其中13種是高危險或癌症的。鱗狀細胞癌是最常見的，佔所有病例的近85%。

鱗狀細胞癌和腺癌的區分是基於顯微鏡下觀察的組織學圖像。子宮頸腺鱗癌很罕見，包含鱗狀和腺組織的混合物。子宮頸癌的治療方法大致分為預防和治療。為了預防，有針對 HPV 的疫苗。目前市面上有兩種疫苗： Gardasil和Cervarix。治療選擇包括Avastin等生物製藥和拓撲替康、Cisplatin、博來黴素、Fluorouracil、紫杉醇、Carboplatin和阿黴素等學名藥。開發具有提高療效和降低成本的標靶治療仍然是該市場中未滿足的主要需求。然而，對包括子宮頸癌在內的腫瘤學研發的日益關注表明該市場的未來充滿希望。

子宮頸癌治療市場報告亮點

  • 鱗狀細胞癌類型佔市場主導地位，2023年佔最大銷售佔有率，為71.1%。這種成長是由於高風險人類乳突病毒 (HPV) 亞型（主要是 HPV 16 和 18）持續感染所致，這兩種亞型佔病例的大多數。
  • 化療治療引領市場，2023年佔最大銷售佔有率，達33.9%。這種成長歸因於藥物開發的進步，大大增加了子宮頸腺癌的治療選擇。
  • 醫院和診所細分市場佔據主導地位，2023 年收益佔有率最大，為 65.0%。這一成長歸因於醫院和診所的分娩程序的加強，包括標靶治療、放射線治療、免疫療法、微創手術和許多其他方法。
  • 北美子宮頸癌治療市場主導全球市場，2023年佔最大銷售佔有率，達39.4%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章子宮頸癌治療市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 子宮頸癌治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章子宮頸癌治療市場：按類型估計和趨勢分析

  • 細分儀表板
  • 子宮頸癌治療市場波動分析：按類型，2023 年和 2030 年
  • 鱗狀細胞癌
  • 腺癌
  • 腺鱗癌
  • 其他

第5章子宮頸癌治療市場：依治療分類的估計與趨勢分析

  • 細分儀表板
  • 子宮頸癌治療市場波動分析：依治療方式，2023 年和 2030 年
  • 放射治療
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他

第6章子宮頸癌治療市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 子宮頸癌治療市場波動分析：依最終用途分類，2023 年和 2030 年
  • 醫院/診所
  • 門診手術中心
  • 其他

第7章子宮頸癌治療市場：依地區估算及趨勢分析

  • 2023 年和 2030 年按地區分類的子宮頸癌治療市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Merck &Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Eli Lilly and Company.
    • Novartis AG
    • AstraZeneca
    • GSK plc.
    • AbbVie Inc.
    • Johnson &Johnson Services, Inc.
簡介目錄
Product Code: GVR-2-68038-718-6

Cervical Cancer Treatment Market Growth & Trends:

The global cervical cancer treatment market size is expected to reach USD 11.74 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increased treatment penetration and rising disease incidence are projected to drive the market growth over the next few years. Although, sexually transmitted HPV is a major cause, the disease can also be triggered by other factors, such as oral contraceptives, multiple sexual partners, smoking, and HIV infection. There are more than 100 strains of HPV, 13 of which are high-risk or cancerous. Squamous cell carcinoma is the most common type and it accounts for nearly 85% of the overall cases.

The differentiation between squamous cell carcinoma and adenocarcinoma is based on the histology, as observed under the microscope. Cervical adenosquamous carcinoma is rare, involving a mixture of squamous and glandular tissues. Products for cervical cancer can be broadly classified into prevention and treatment. Preventive options involve vaccines against HPV. Currently, there are two commercial vaccines - Gardasil and Cervarix. Treatment options include biologics, such as Avastin and generics like topotecan, cisplatin, bleomycin, fluorouracil, paclitaxel, carboplatin, and doxorubicin. The development of targeted therapeutics with improved efficacy and reduced cost remains a key unmet need of this market. Nevertheless, expanding focus on the research and development in oncology, including cervical cancer, indicate a promising future for this market.

Cervical Cancer Treatment Market Report Highlights:

  • Squamous cell carcinoma type dominated the market and accounted for the largest revenue share of 71.1% in 2023. This growth is attributed to persistent infection with high-risk human papillomavirus (HPV) subtypes, mainly HPV 16 and 18, which account for most cases.
  • Chemotherapy treatment led the market and accounted for the largest revenue share of 33.9% in 2023. This growth is attributed to the advancements in drug development that have significantly enhanced treatment options for cervical adenocarcinoma.
  • Hospitals & clinics segment dominated the market and accounted for the largest revenue share of 65.0% in 2023. This growth is attributed to the enhanced delivery procedures in hospitals & clinics with offerings such as targeted therapy, radiation therapy, immunotherapy, minimally invasive surgeries, and many other methods.
  • The North America cervical cancer treatment market dominated the global market and accounted for the largest revenue share of 39.4% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cervical Cancer Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cervical Cancer Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cervical Cancer Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cervical Cancer Treatment Market: Type Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Squamous Cell Carcinoma
    • 4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Adenocarcinoma
    • 4.4.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Adenosquamous Carcinoma
    • 4.5.1. Adenosquamous Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Types
    • 4.6.1. Other Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cervical Cancer Treatment Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cervical Cancer Treatment Market: Treatment Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Radiation Therapy
    • 5.3.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. External Beam Radiation Therapy (EBRT)
      • 5.3.2.1. External Beam Radiation Therapy (EBRT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Brachytherapy
      • 5.3.3.1. Brachytherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Cisplatin
      • 5.4.2.1. Cisplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Carboplatin
      • 5.4.3.1. Carboplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Paclitaxel
      • 5.4.4.1. Paclitaxel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. Other Chemotherapeutic Agents
      • 5.4.5.1. Other Chemotherapeutic Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Bevacizumab (Avastin)
      • 5.5.2.1. Bevacizumab (Avastin) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Other Targeted Therapies
      • 5.5.3.1. Other Targeted Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Pembrolizumab (Keytruda)
      • 5.6.2.1. Pembrolizumab (Keytruda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. Other Immune Checkpoint Inhibitors
      • 5.6.3.1. Other Immune Checkpoint Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other Therapies
    • 5.7.1. Other Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cervical Cancer Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cervical Cancer Treatment Market: End Use Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospitals & Clinics
    • 6.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Ambulatory Surgery Centers
    • 6.4.1. Ambulatory Surgery Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cervical Cancer Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Cervical Cancer Treatment Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Merck & Co., Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Bristol-Myers Squibb Company
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. F. Hoffmann-La Roche Ltd
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Pfizer Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Eli Lilly and Company.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. AstraZeneca
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. GSK plc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. AbbVie Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Johnson & Johnson Services, Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives